跳至主要内容
临床试验/ACTRN12618001120268
ACTRN12618001120268终止3 期

Zinc in Preventing the Progression of Pre-Diabetes

Professsor John Attia0 个研究点目标入组 98 人开始时间: 2018年7月6日最近更新:
适应症

试验速览

阶段
3 期
状态
终止
发起方
入组人数
98

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 70 Years(—)
性别
All

入选标准

  • Prediabetes, defined by a HbA1c of 5.7-6.4

排除标准

  • One or more of the following:
  • Taking any other vitamin or mineral supplementation containing zinc;
  • Currently using weight loss medication;
  • Pregnancy or lactation for women of child-bearing age;
  • Impaired hepatic or renal function;
  • Taking pharmacology agents that may interfere with the intervention (for example, metformin, and complementary medicines).
  • Any condition that, in the opinion of the investigator, does not justify the patient’s inclusion in the study (current cancer under treatment, terminal cancer, terminal illness).
  • Persons who are unable to read and understand the information statement and consent form are ineligible. Informed consent must be obtained to be eligible for the study.

研究者

发起方
Professsor John Attia

相似试验